Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

18 trials with published results (7%)

Research Maturity

101 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.4%

13 terminated out of 242 trials

Success Rate

88.6%

+2.0% vs benchmark

Late-Stage Pipeline

8%

19 trials in Phase 3/4

Results Transparency

18%

18 of 101 completed with results

Key Signals

18 with results89% success13 terminated

Data Visualizations

Phase Distribution

192Total
Not Applicable (65)
P 1 (30)
P 2 (78)
P 3 (16)
P 4 (3)

Trial Status

Completed101
Unknown74
Recruiting29
Terminated13
Not Yet Recruiting9
Active Not Recruiting9

Trial Success Rate

88.6%

Benchmark: 86.5%

Based on 101 completed trials

Clinical Trials (242)

Showing 20 of 20 trials
NCT07213791Phase 1Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT07749326Not ApplicableRecruitingPrimary

Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (KLASS 16)

NCT07114601Phase 1Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT01950572Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT07741435Recruiting

Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia

NCT06885697Phase 1Recruiting

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06157892Phase 2Active Not Recruiting

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06131840Phase 1Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT07714980Not ApplicableNot Yet Recruiting

TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)

NCT07687394Phase 4Not Yet RecruitingPrimary

A Phase IV Randomized Trial of Maxigesic® Versus Standard Analgesia After Radical Gastrectomy

NCT04389632Phase 1Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT07682220Not ApplicableCompleted

Default Option Nudging Intervention to Improve the Adherence Rates of Cancer Screening

NCT06630130Phase 2RecruitingPrimary

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

NCT07664813Not ApplicableNot Yet RecruitingPrimary

One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy

NCT05334719CompletedPrimary

A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer

NCT06504732Phase 2RecruitingPrimary

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

NCT03030404CompletedPrimary

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

NCT07607119Not ApplicableRecruiting

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

NCT07586384Not ApplicableRecruitingPrimary

Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial

NCT07007182Phase 2Recruiting

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Scroll to load more

Research Network

Activity Timeline